HOMEPRODUCTSSERVICESCOMPANYCONTACTFAQResearchDictionaryPharmaMobileSign Up FREE or Login

Stephen T Keir Selected Research

Heterologous Transplantation (Xenotransplantation)

6/2015Initial testing (stage 1) of BAL101553, a novel tubulin binding agent, by the pediatric preclinical testing program.
6/2015Proteomic profiling of patient-derived glioblastoma xenografts identifies a subset with activated EGFR: implications for drug development.
2/2015Synergistic activity of PARP inhibition by talazoparib (BMN 673) with temozolomide in pediatric cancer models in the pediatric preclinical testing program.
12/2014Profiling Hsp90 differential expression and the molecular effects of the Hsp90 inhibitor IPI-504 in high-grade glioma models.
11/2014Initial solid tumor testing (stage 1) of AZD1480, an inhibitor of Janus kinases 1 and 2 by the pediatric preclinical testing program.
8/2014Initial testing (stage 1) of the investigational mTOR kinase inhibitor MLN0128 by the pediatric preclinical testing program.
8/2014Initial testing (stage 1) of the notch inhibitor PF-03084014, by the pediatric preclinical testing program.
2/2014Initial testing (stage 1) of the histone deacetylase inhibitor, quisinostat (JNJ-26481585), by the Pediatric Preclinical Testing Program.
1/2014Initial testing (stage 1) of the Polo-like kinase inhibitor volasertib (BI 6727), by the Pediatric Preclinical Testing Program.
12/2013Proteasome inhibition with bortezomib induces cell death in GBM stem-like cells and temozolomide-resistant glioma cell lines, but stimulates GBM stem-like cells' VEGF production and angiogenesis.
For more, sign up at right for free...

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research network!


Choose Username:
Email:
Password:
Verify Password:


Stephen T Keir Research Topics

Disease

78Neoplasms (Cancer)
12/2015 - 05/2003
20Glioblastoma (Glioblastoma Multiforme)
06/2015 - 01/2005
18Glioma (Gliomas)
06/2015 - 05/2003
17Sarcoma (Soft Tissue Sarcoma)
02/2015 - 04/2008
15Neuroblastoma
01/2014 - 03/2008
14Rhabdomyosarcoma
01/2014 - 11/2005
12Leukemia
02/2015 - 06/2008
11Brain Neoplasms (Brain Tumor)
12/2015 - 05/2003
11Osteosarcoma (Osteogenic Sarcoma)
08/2013 - 03/2008
11Precursor Cell Lymphoblastic Leukemia-Lymphoma (Acute Lymphoblastic Leukemia)
08/2012 - 01/2008
7Wilms Tumor (Wilm's Tumor)
11/2014 - 05/2008
7Medulloblastoma
11/2013 - 07/2007
5Rhabdoid Tumor (Rhabdoid Tumors)
07/2010 - 05/2008
3Anoxia (Hypoxia)
12/2013 - 02/2010
3Alveolar Rhabdomyosarcoma
04/2013 - 07/2008
2Ependymoma
08/2011 - 11/2005
2Weight Loss (Weight Reduction)
07/2007 - 09/2006
1Ovarian Neoplasms (Ovarian Cancer)
12/2014
1Sudden Infant Death (SID)
11/2014
1Oligodendroglioma
03/2014
1Stomach Neoplasms (Stomach Cancer)
11/2013
1Lymphoma (Lymphomas)
11/2013
1Myeloid Leukemia (Leukemia, Myelocytic)
10/2012

Drug/Important Bio-Agent (IBA)

33N- propyl- 4- phenyl- 1,2,3,6- tetrahydropyridine (PPTP)IBA
01/2015 - 12/2007
8Phosphotransferases (Kinase)IBA
12/2015 - 01/2005
7temozolomide (Temodar)FDA LinkGeneric
06/2015 - 05/2003
6Sirolimus (Rapamycin)FDA Link
05/2012 - 01/2005
5Epidermal Growth Factor Receptor (EGF Receptor)IBA
12/2015 - 01/2005
4Vascular Endothelial Growth Factor A (Vascular Endothelial Growth Factor)IBA
12/2014 - 09/2006
4Immunotoxins (Immunotoxin)IBA
09/2013 - 07/2011
3Tyrosine (L-Tyrosine)FDA Link
12/2015 - 06/2007
3Topotecan (Hycamtin)FDA LinkGeneric
11/2013 - 05/2010
3Vincristine (Oncovin)FDA LinkGeneric
08/2013 - 12/2007
3Vascular Endothelial Growth Factor Receptors (VEGF Receptors)IBA
12/2010 - 11/2005
2Protein Kinases (Protein Kinase)IBA
12/2014 - 09/2007
2Messenger RNA (mRNA)IBA
12/2014 - 02/2012
2Proteins (Proteins, Gene)IBA
12/2014 - 07/2008
2MicroRNAs (MicroRNA)IBA
10/2014 - 01/2011
2bortezomib (Velcade)FDA Link
12/2013 - 01/2008
2bevacizumabFDA Link
12/2013 - 12/2010
2Proteasome Endopeptidase Complex (Proteasome)IBA
12/2013 - 01/2008
2DNA (Deoxyribonucleic Acid)IBA
05/2013 - 09/2010
2CytotoxinsIBA
04/2012 - 01/2010
2Cyclophosphamide (Cytoxan)FDA LinkGeneric
04/2012 - 12/2007
24- ((4- Fluoro- 2- methyl- 1H- indol- 5- yl)oxy)- 6- methoxy- 7- (3- (pyrrolidin- 1- yl)propoxy)quinazoline (AZD2171)IBA
04/2012 - 03/2008
2Cisplatin (Platino)FDA LinkGeneric
04/2012 - 05/2008
2MLN 8237IBA
11/2011 - 07/2010
2Protein-Tyrosine Kinases (Tyrosine Kinase)IBA
10/2009 - 11/2005
2laromustine (VNP40101M)IBA
09/2008 - 07/2007
2everolimusFDA Link
09/2007 - 01/2005
2tyrosine receptor (receptor, tyrosine)IBA
06/2007 - 01/2005
2Vascular Endothelial Growth Factor Receptor-2 (Vascular Endothelial Growth Factor Receptor 2)IBA
11/2005 - 01/2005
1Glutathione Transferase (Glutathione S-Transferase)IBA
12/2015
1Poly(ADP-ribose) Polymerases (Poly ADP Ribose Polymerase)IBA
01/2015
1Heat-Shock Proteins (Heat-Shock Protein)IBA
12/2014
117-(allylamino)-17-demethoxygeldanamycin (17AAG)IBA
12/2014
1AZD1480IBA
11/2014
1Angiogenesis InhibitorsIBA
11/2014
1Janus KinasesIBA
11/2014
1Adenosine Triphosphate (ATP)IBA
11/2014
12- (5,7- difluoro- 1,2,3,4- tetrahydronaphthalen- 3- ylamino)- N- (1- (2- methyl- 1- (neopentylamino)propan- 2- yl)- 1H- imidazol- 4- yl)pentanamideIBA
08/2014
1Isocitrate Dehydrogenase (Isocitrate Dehydrogenase (NAD+))IBA
03/2014
1Telomerase (Telomerase Reverse Transcriptase)IBA
03/2014
1Carbon MonoxideIBA
03/2014
1polo-like kinase 1IBA
01/2014
1BI 6727IBA
01/2014
1Caspase 3 (Caspase-3)IBA
12/2013
1histone methyltransferaseIBA
11/2013
1Lysine (L-Lysine)FDA Link
11/2013
1Kabuki syndromeIBA
11/2013
1epidermal growth factor receptor VIIIIBA
09/2013
1GangliosidesIBA
09/2013
12- (3- amino- 2- hydroxypropyl)hexacosahydro- 3- methoxy- 26- methyl- 20,27- bis(methylene)11,15- 18,21- 24,28- triepoxy- 7,9- ethano- 12,15- methano- 9H,15H- furo(3,2- i)furo(2',3'- 5,6)pyrano(4,3- b)(1,4)dioxacyclopentacosin- 5- (4H)- oneIBA
08/2013
1Antimitotic AgentsIBA
08/2013
1AntigensIBA
05/2013
1AMP-Activated Protein KinasesIBA
03/2013
1T-Type Calcium Channels (T-Type Calcium Channel)IBA
01/2013
1MibefradilIBA
01/2013
1KM-233IBA
11/2012
1Antineoplastic Agents (Antineoplastics)IBA
11/2012
1SGI 1776IBA
10/2012
1Platelet-Derived Growth Factor Receptors (Platelet-Derived Growth Factor Receptor)IBA
09/2012
1pazopanibIBA
09/2012
1MK 2206IBA
09/2012
1((1S,2S,4R)- 4- (4- ((1S)- 2,3- dihydro- 1H- inden- 1- ylamino)- 7H- pyrrolo(2,3- d)pyrimidin- 7- yl)- 2- hydroxycyclopentyl)methyl sulphamateIBA
08/2012
1(2,4- dihydroxy- 5- isopropylphenyl)- (5- (4- methylpiperazin- 1- ylmethyl)- 1,3- dihydroisoindol- 2- yl)methanoneIBA
07/2012
1KinesinIBA
06/2012
1IGF Type 1 Receptor (IGF 1 Receptor)IBA
05/2012
12,2- dimethyl- N- (6- oxo- 6,7- dihydro- 5H- dibenzo(b,d)azepin- 7- yl)- N'- (2,2,3,3,3- pentafluoropropyl)malonamideIBA
05/2012
1AntibodiesIBA
05/2012
1Somatomedin Receptors (Somatomedin Receptor)IBA
05/2012
1(5- (2,4- bis((3S)- 3- methylmorpholin- 4- yl)pyrido(2,3- d)pyrimidin- 7- yl)- 2- methoxyphenyl)methanolIBA
02/2012

Therapy/Procedure

67Heterologous Transplantation (Xenotransplantation)
06/2015 - 05/2003
4Drug Therapy (Chemotherapy)
12/2013 - 09/2010
2Immunotherapy
09/2013 - 07/2011
2Withholding Treatment
07/2008 - 06/2008
1Investigational Therapies (Experimental Therapy)
06/2015
1Subcutaneous Injections
12/2013
1Therapeutics
11/2013
1Radiotherapy
05/2013